دورية أكاديمية
In Vitro Susceptibility and Resistance of Mycoplasma genitalium to Nitroimidazoles.
العنوان: | In Vitro Susceptibility and Resistance of Mycoplasma genitalium to Nitroimidazoles. |
---|---|
المؤلفون: | Wood GE; Department of Medicine, Division of Allergy and Infectious Diseases, University of Washington, Seattle, Washington, USA., Kim CM; Department of Medicine, Division of Allergy and Infectious Diseases, University of Washington, Seattle, Washington, USA., Aguila LKT; Department of Medicine, Division of Allergy and Infectious Diseases, University of Washington, Seattle, Washington, USA., Cichewicz RH; Department of Chemistry and Biochemistry, University of Oklahoma, Norman, Oklahoma, USA.; Natural Products Discovery Group, University of Oklahoma, Norman, Oklahoma, USA.; Institute for Natural Products Applications and Research Technologies, University of Oklahoma, Norman, Oklahoma, USA. |
المصدر: | Antimicrobial agents and chemotherapy [Antimicrob Agents Chemother] 2023 Apr 18; Vol. 67 (4), pp. e0000623. Date of Electronic Publication: 2023 Mar 09. |
نوع المنشور: | Journal Article; Research Support, N.I.H., Extramural |
اللغة: | English |
بيانات الدورية: | Publisher: American Society for Microbiology Country of Publication: United States NLM ID: 0315061 Publication Model: Print-Electronic Cited Medium: Internet ISSN: 1098-6596 (Electronic) Linking ISSN: 00664804 NLM ISO Abbreviation: Antimicrob Agents Chemother Subsets: MEDLINE |
أسماء مطبوعة: | Original Publication: Washington, American Society for Microbiology |
مواضيع طبية MeSH: | Nitroimidazoles*/pharmacology , Nitroimidazoles*/therapeutic use , Mycoplasma genitalium*/genetics , Mycoplasma Infections*/drug therapy, Male ; Female ; Humans ; Doxycycline/pharmacology ; Doxycycline/therapeutic use ; Metronidazole/pharmacology ; Metronidazole/therapeutic use ; Tinidazole/pharmacology ; Tinidazole/therapeutic use ; Anti-Bacterial Agents/pharmacology ; Anti-Bacterial Agents/therapeutic use ; Drug Resistance, Bacterial/genetics |
مستخلص: | Mycoplasma genitalium is a sexually transmitted reproductive tract pathogen of men and women. M. genitalium infections are increasingly difficult to treat due to poor efficacy of doxycycline and acquired resistance to azithromycin and moxifloxacin. A recent clinical trial suggested that metronidazole may improve cure rates for women with pelvic inflammatory disease and reduced the detection of M. genitalium when included with standard doxycycline plus ceftriaxone treatment. As data regarding susceptibility of mycoplasmas to nitroimidazoles are lacking in the scientific literature, we determined the in vitro susceptibility of 10 M. genitalium strains to metronidazole, secnidazole, and tinidazole. MICs ranged from 1.6 to 12.5 μg/mL for metronidazole, 3.1 to 12.5 μg/mL for secnidazole, and 0.8 to 6.3 μg/mL for tinidazole. None of these agents was synergistic with doxycycline in checkerboard broth microdilution assays. Tinidazole was superior to metronidazole and secnidazole in terms of MIC and time-kill kinetics and was bactericidal (>99.9% killing) at concentrations below reported serum concentrations. Mutations associated with nitroimidazole resistance were identified by whole-genome sequencing of spontaneous resistant mutants, suggesting a mechanism for reductive activation of the nitroimidazole prodrug by a predicted NAD(P)H-dependent flavin mononucleotide (FMN) oxidoreductase. The presence of oxygen did not affect MICs of wild-type M. genitalium, but a nitroimidazole-resistant mutant was defective for growth under anaerobic conditions, suggesting that resistant mutants may have a fitness disadvantage in anaerobic genital sites. Clinical studies are needed to determine if nitroimidazoles, especially tinidazole, are effective for eradicating M. genitalium infections in men and women. |
References: | Lancet. 1983 Dec 17;2(8364):1379-82. (PMID: 6140492) Clin Infect Dis. 2021 Apr 8;72(7):1181-1189. (PMID: 32052831) Cell Rep Methods. 2021 Jul 26;1(3):. (PMID: 34355210) Clin Infect Dis. 2011 Jan 15;52(2):163-70. (PMID: 21288838) Lancet. 1981 Jun 13;1(8233):1288-91. (PMID: 6112607) J Antimicrob Chemother. 2003 Jul;52(1):1. (PMID: 12805255) Parasitology. 2019 Aug;146(9):1150-1155. (PMID: 30616707) Clin Infect Dis. 2021 Apr 8;72(7):1190-1191. (PMID: 32052829) Biology (Basel). 2021 May 01;10(5):. (PMID: 34062712) Mol Microbiol. 2007 Oct;66(1):55-73. (PMID: 17880423) Science. 1977 Mar 4;195(4281):892-4. (PMID: 841314) Infect Immun. 2006 Jul;74(7):3715-26. (PMID: 16790744) BMC Infect Dis. 2015 Aug 19;15:343. (PMID: 26286546) Bioinformatics. 2009 Aug 15;25(16):2078-9. (PMID: 19505943) Mol Syst Biol. 2015 Jan 21;11(1):780. (PMID: 25609650) Infect Immun. 2017 Jan 26;85(2):. (PMID: 27872239) Proc Natl Acad Sci U S A. 2006 Jan 10;103(2):425-30. (PMID: 16407165) PLoS Genet. 2009 Oct;5(10):e1000677. (PMID: 19816563) Antimicrob Agents Chemother. 2003 Jan;47(1):161-5. (PMID: 12499185) Br J Pharmacol. 2017 Jul;174(14):2161-2173. (PMID: 27487252) Exp Cell Res. 2020 Jun 1;391(1):111973. (PMID: 32209305) J Clin Microbiol. 2021 Oct 19;59(11):e0081921. (PMID: 34406799) Nucleic Acids Res. 2017 Jul 3;45(W1):W291-W299. (PMID: 28472402) Sex Transm Dis. 2019 Jan;46(1):18-24. (PMID: 29979336) N Engl J Med. 1978 Jun 29;298(26):1429-34. (PMID: 306577) Infection. 1984 May-Jun;12(3):197-201. (PMID: 6469365) Antimicrob Agents Chemother. 2005 Dec;49(12):4993-8. (PMID: 16304163) J Med Chem. 2017 Sep 28;60(18):7636-7657. (PMID: 28463485) J Clin Microbiol. 2014 Dec;52(12):4124-8. (PMID: 24920779) MMWR Recomm Rep. 2021 Jul 23;70(4):1-187. (PMID: 34292926) J Clin Microbiol. 2004 Feb;42(2):683-92. (PMID: 14766837) PLoS One. 2015 May 26;10(5):e0127911. (PMID: 26010086) Clin Infect Dis. 2019 Feb 1;68(4):554-560. (PMID: 29873691) PLoS One. 2015 Sep 18;10(9):e0138244. (PMID: 26381903) Lancet Infect Dis. 2020 Nov;20(11):1302-1314. (PMID: 32622378) J Med Microbiol. 2004 Nov;53(Pt 11):1123-1128. (PMID: 15496391) Nucleic Acids Res. 2015 Jul 1;43(W1):W174-81. (PMID: 25883148) Sex Transm Dis. 1983 Oct-Dec;10(4 Suppl):374-81. (PMID: 6229892) Clin Infect Dis. 2015 Aug 1;61(3):418-26. (PMID: 25900174) J Infect Dis. 2017 Jul 15;216(suppl_2):S396-S405. (PMID: 28838074) Nat Biotechnol. 2011 Jan;29(1):24-6. (PMID: 21221095) Antimicrob Agents Chemother. 1994 Sep;38(9):2054-8. (PMID: 7811018) Nat Commun. 2016 Apr 15;7:11307. (PMID: 27079541) Curr Opin Struct Biol. 1996 Jun;6(3):377-85. (PMID: 8804824) Antimicrob Agents Chemother. 2009 Nov;53(11):4938-9. (PMID: 19738019) |
معلومات مُعتمدة: | R21 AI153863 United States AI NIAID NIH HHS |
فهرسة مساهمة: | Keywords: Mycoplasma genitalium; antibiotic resistance; metronidazole; nitroimidazole; secnidazole; tinidazole |
المشرفين على المادة: | 0 (Nitroimidazoles) N12000U13O (Doxycycline) R3459K699K (secnidazole) 140QMO216E (Metronidazole) 033KF7V46H (Tinidazole) 0 (Anti-Bacterial Agents) |
تواريخ الأحداث: | Date Created: 20230418 Date Completed: 20230420 Latest Revision: 20230421 |
رمز التحديث: | 20231215 |
مُعرف محوري في PubMed: | PMC10112249 |
DOI: | 10.1128/aac.00006-23 |
PMID: | 37070857 |
قاعدة البيانات: | MEDLINE |
تدمد: | 1098-6596 |
---|---|
DOI: | 10.1128/aac.00006-23 |